Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: An analysis of a large US claims database

Current Medical Research and Opinion

Volumn 30, Issue 12, 2014, Pages 2515-2521

  Wendling, Daniel ^a   Joshi, Avani ^b   Reilly, Patrick ^b   Jalundhwala, Yash J ^c   Mittal, Manish ^b   Bao, Yanjun ^b  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b ABBVIE INC   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Ankylosing spondylitis; Anti tumor necrosis factor; Extra articular manifestation; Retrospective study; Uveitis

Indexed keywords

ADALIMUMAB; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN G; INFLIXIMAB; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

COMPARATIVE STUDY; COMPLICATION; FACTUAL DATABASE; FEMALE; HUMAN; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RISK; SPONDYLITIS, ANKYLOSING; UNITED STATES; UVEITIS; YOUNG ADULT;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DATABASES, FACTUAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RISK; SPONDYLITIS, ANKYLOSING; UNITED STATES; UVEITIS; YOUNG ADULT;

EID: 84914146023     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.969368     Document Type: Article

References (36)

1. Elewaut D, Matucci-Cerinic M. Treatment of ankylosing spondylitis and extraarticular manifestations in everyday rheumatology practice. Rheumatology (Oxford) 2009;48:1029-35
2. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res 2011;63:550-6
3. Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extraarticular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 2013: published online 2 September 2013, doi: 10.1136/annrheumdis-2013-203582
4. Rosenbaum JT, Smith JR. Anti-TNF therapy for eye involvement in spondyloarthropathy. Clin Exp Rheumatol 2002;20(6 Suppl 28):S143-5
5. Hamideh F, Prete PE. Ophthalmologic manifestations of rheumatic diseases. Semin Arthritis Rheum 2001;30:217-41
6. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis 2008;67:955-9
7. Vander Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7
8. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93
9. Pato E, Bañares A, Jover JA, et al. Undiagnosed spondyloarthropathy in patients presenting with anterior uveitis. J Rheumatol 2000;27:2198-202
10. Ferná ndez-Meló n J, Muñoz-Ferná ndez S, Hidalgo V, et al. Uveitis as the initial clinical manifestation in patients with spondyloarthropathies. J Rheumatol 2004;31:524-7
11. Derhaag PJ, van der Horst AR, de Waal LP, Feltkamp TE. HLA-B27+ acute anterior uveitis and other antigens of the major histocompatibility complex. Invest Ophthalmol Vis Sci 1989;30:2160-4
12. Wendling D. Uveitis in seronegative arthritis. Curr Rheumatol Rep 2012;14:402-8
13. Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol 2001;119:841-9
14. Kirson NY, Rao S, Eldar-Lissai A, et al. Impact of extra-articular manifestations (EAMs) on medical resource utilization and cost of care for ankylosing spondylitis (AS) patients [abstract]. Ann Rheum Dis 2011;70(Suppl 3):428
15. Hajj-Ali RA, Lowder C, Mandell BF. Uveitis in the internist's office: are a patient's eye symptoms serious? Cleve Clin J Med 2005;72:329-39
16. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-a in clinical uveitis. Ophthalmic Res 2001;33:251-5
17. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505
18. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-6
19. Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 2014;121:785-96
20. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52: 2447-51
21. Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701
22. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumor necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4
23. Horst-Bruinsma IE, van Denderen JC, Visman I, et al. Decreased recurrence rate of anterior uveitis in ankylosing spondylitis treated with adalimumab: an interim analysis [abstract]. Arthritis Rheum 2010;62(Suppl 10):1933
24. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52
25. Wendling D, Paccou J, Berthelot J-M, et al. New onset of uveitis during antitumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10
26. Sieper J, Koenig A, Baumgartner S, et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010;69:226-9
27. Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocul Immunol Inflamm 2010;18:116-20
28. Dougados M, Berenbaum F, Maetzel A, Amor B. Prevention of acute anterior uveitis associated with spondyloarthropathy induced by salazosulfapyridine [in French]. Rev Rhum Ed Fr 1993;60:81-3
29. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Bañares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 2000;14:340-3
30. Muñoz-Ferná ndez-Meló n S, Hildago V, Ferná ndez-Meló n J, et al. Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 2003;30:1277-9
31. Berg IJ, Semb AG, van der Heijde D, et al. Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: a crosssectional study. Semin Arthritis Rheum 2014: published online 20 May 2014, doi: 10.1016/j.semarthrit.2014.05.017
32. Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29:664-74
33. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-12
34. Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-61
35. Perez-Alvarez R, Pé rez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25:56-64
36. Wendling D, Prati C. Paradoxical effects of anti-TNF-a agents in inflammatory diseases. Expert Rev Clin Immunol 2014;10:159-69